Regulus Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Regulus Therapeutics

04/11/2022 17:11

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 10. 
    * 
    * ​Refinitiv's mean analyst estimate for Regulus
Therapeutics Inc
is for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $20​, above​ its last closing price
of $1.37. ​​​

This summary was machine generated November 4 at 17:11 GMT.  All
figures in US dollars  unless otherwise stated